Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis

Detalhes bibliográficos
Autor(a) principal: Francesconi, G.
Data de Publicação: 2009
Outros Autores: Valle, A. C., Passos, S., Reis, R., Galhardo, M. C.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/33266
Resumo: 2020-05-29
id CRUZ_45ed9f74b38cd93d85dfee2678d9a578
oai_identifier_str oai:www.arca.fiocruz.br:icict/33266
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Francesconi, G.Valle, A. C.Passos, S.Reis, R.Galhardo, M. C.2019-05-29T14:16:41Z2019-05-29T14:16:41Z2009FRANCESCONI, G. et al. Terbinafine (250 mg/day): an effective and safe treatmentof cutaneous sporotrichosis. Journal of the European Academy of Dermatology and Venereology, v. 23, p. 1273-1276, Nov. 2009.0926-9959https://www.arca.fiocruz.br/handle/icict/3326610.1111/j.1468-3083.2009.03306.x1468-3083engWileyTerbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2020-05-29Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Epidemiologia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.There are a few studies on the treatment of sporotrichosis. The standard drug used is itraconazole. However, the use of itraconazole is limited by its interaction with other drugs.ObjectiveTo evaluate the effectiveness and safety of 250 mg terbinafine for the treatment of cutaneous sporotrichosisin patients in whom itraconazole use is not possible.MethodsWe performed a descriptive study of cutaneous sporotrichosis cases treated with 250 mg terbinafine for whichitraconazole was contraindicated or resulted in severe or moderate pharmacological interactions. Sporotrichosis wasdiagnosedbasedontheisolationofS. schenckii.ResultsFifty patients seen between July 2005 and September 2007 were included. Forty-five (92%) patients reportedcontact with a sick cat and 47 (94%) presented comorbidities (high blood pressure: 64.0%; diabetes mellitus: 30.0%;dyslipidemia: 16.7%; depression: 10.0%; migraine: 2.1%; Parkinsonı ́s disease: 2.1%; peptic ulcer disease: 2.1%; heartfailure: 2.1%, and arrhythmia: 2.1%). All patients used some medication interacting with itraconazole (psycholeptics:36.0%; antidiabetic agents: 28.0%; hypolipemiant agents: 18.0%; calcium-channel blockers: 16.0%; anticonvulsants:8.0%; cardiotropic drugs: 6.3%; antacids: 6.3%, and antiparkinsonian agent: 2.1%). Most patients (96%) were curedwithin a mean period of 14 weeks. The drug was discontinued due to a skin rash in one patient. There were no cases ofrecurrence of the mycosis within a mean follow-up period of 37 weeks.ConclusionsThis study suggests that 250 mg/day terbinafine is an effective and well-tolerated alternative to drugtherapy of cutaneous sporotrichosis in a population in which itraconazole use is not possible.ItraconazoleSporotrichosisTerbinafineTreatmentinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83104https://www.arca.fiocruz.br/bitstream/icict/33266/1/license.txt79178e5f2a0eb066867a274556814938MD51ORIGINALve_Francesconi_G_etal_INI_2009.pdfve_Francesconi_G_etal_INI_2009.pdfapplication/pdf80554https://www.arca.fiocruz.br/bitstream/icict/33266/2/ve_Francesconi_G_etal_INI_2009.pdf84fb8d1ab147f6c73705054190f17448MD52TEXTve_Francesconi_G_etal_INI_2009.pdf.txtve_Francesconi_G_etal_INI_2009.pdf.txtExtracted texttext/plain20286https://www.arca.fiocruz.br/bitstream/icict/33266/3/ve_Francesconi_G_etal_INI_2009.pdf.txtc66c83506ac6fa407854052741614c4eMD53icict/332662021-03-24 16:32:32.433oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-03-24T19:32:32Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis
title Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis
spellingShingle Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis
Francesconi, G.
Itraconazole
Sporotrichosis
Terbinafine
Treatment
title_short Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis
title_full Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis
title_fullStr Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis
title_full_unstemmed Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis
title_sort Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis
author Francesconi, G.
author_facet Francesconi, G.
Valle, A. C.
Passos, S.
Reis, R.
Galhardo, M. C.
author_role author
author2 Valle, A. C.
Passos, S.
Reis, R.
Galhardo, M. C.
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Francesconi, G.
Valle, A. C.
Passos, S.
Reis, R.
Galhardo, M. C.
dc.subject.en.pt_BR.fl_str_mv Itraconazole
Sporotrichosis
Terbinafine
Treatment
topic Itraconazole
Sporotrichosis
Terbinafine
Treatment
description 2020-05-29
publishDate 2009
dc.date.issued.fl_str_mv 2009
dc.date.accessioned.fl_str_mv 2019-05-29T14:16:41Z
dc.date.available.fl_str_mv 2019-05-29T14:16:41Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv FRANCESCONI, G. et al. Terbinafine (250 mg/day): an effective and safe treatmentof cutaneous sporotrichosis. Journal of the European Academy of Dermatology and Venereology, v. 23, p. 1273-1276, Nov. 2009.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/33266
dc.identifier.issn.pt_BR.fl_str_mv 0926-9959
dc.identifier.doi.none.fl_str_mv 10.1111/j.1468-3083.2009.03306.x
dc.identifier.eissn.none.fl_str_mv 1468-3083
identifier_str_mv FRANCESCONI, G. et al. Terbinafine (250 mg/day): an effective and safe treatmentof cutaneous sporotrichosis. Journal of the European Academy of Dermatology and Venereology, v. 23, p. 1273-1276, Nov. 2009.
0926-9959
10.1111/j.1468-3083.2009.03306.x
1468-3083
url https://www.arca.fiocruz.br/handle/icict/33266
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/33266/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/33266/2/ve_Francesconi_G_etal_INI_2009.pdf
https://www.arca.fiocruz.br/bitstream/icict/33266/3/ve_Francesconi_G_etal_INI_2009.pdf.txt
bitstream.checksum.fl_str_mv 79178e5f2a0eb066867a274556814938
84fb8d1ab147f6c73705054190f17448
c66c83506ac6fa407854052741614c4e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009301639266304

Registros relacionados